Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBIT (2016 - 2025)

Historic EBIT for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$24.0 million.

  • Abeona Therapeutics' EBIT fell 5652.0% to -$24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.2 million, marking a year-over-year decrease of 3697.41%. This contributed to the annual value of -$64.2 million for FY2024, which is 3622.79% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' EBIT is -$24.0 million, which was down 5652.0% from -$22.8 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year EBIT high stood at -$8.0 million for Q2 2022, and its period low was -$46.7 million during Q4 2021.
  • For the 5-year period, Abeona Therapeutics' EBIT averaged around -$16.8 million, with its median value being -$14.6 million (2021).
  • As far as peak fluctuations go, Abeona Therapeutics' EBIT plummeted by 22218.23% in 2021, and later soared by 7227.13% in 2022.
  • Abeona Therapeutics' EBIT (Quarter) stood at -$46.7 million in 2021, then skyrocketed by 72.27% to -$12.9 million in 2022, then fell by 2.11% to -$13.2 million in 2023, then fell by 26.22% to -$16.7 million in 2024, then crashed by 44.06% to -$24.0 million in 2025.
  • Its EBIT stands at -$24.0 million for Q3 2025, versus -$22.8 million for Q2 2025 and -$19.7 million for Q1 2025.